Stay updated with breaking news from Codexis Daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Codexis (NASDAQ:CDXS – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Benchmark in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $9.00 target price on the biotechnology company’s stock. Benchmark’s target price suggests a potential upside of 129.59% from the stock’s current […]
Codexis, Inc. (NASDAQ:CDXS – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have […]
Codexis, Inc. (NASDAQ:CDXS – Get Free Report) has earned an average rating of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among […]
Codexis, Inc. (NASDAQ:CDXS – Get Free Report) has received an average rating of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among […]
Paradigm Capital Management Inc. NY grew its holdings in Codexis, Inc. (NASDAQ:CDXS – Free Report) by 66.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 500,000 shares of the biotechnology company’s stock after buying an additional 200,000 shares during the quarter. Paradigm […]